Related Experiment Video

Updated: Feb 17, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K

Eribulin in advanced breast cancer: safety, efficacy and new perspectives

Ornella Garrone1, Emanuela Miraglio1, Anna Maria Vandone1

  • 1Medical Oncology A.O. S. Croce e Carle Ospedale di Insegnamento, Cuneo, Italy.

Future Oncology (London, England)
|December 9, 2017
PubMed

Insights

Eribulin, a microtubule-targeting agent, shows promise in treating metastatic breast cancer by impacting tumor biology beyond mitosis. Its unique effects on tumor vasculature and epithelial-mesenchymal transition offer new therapeutic avenues.

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Eribulin is a synthetic analog of halichondrin B.
  • It functions as a microtubule-targeted agent with a unique mechanism of inhibiting microtubule dynamics.

Purpose of the Study:

  • To review preclinical and clinical studies on eribulin.
  • To highlight its mitotic and nonmitotic effects on tumor biology.
  • To explore its potential in metastatic breast cancer treatment.

Main Methods:

  • Review of preclinical studies.
  • Review of clinical studies.

Main Results:

  • Eribulin exhibits distinct inhibition of microtubule dynamics.
  • It demonstrates nonmitotic effects, including impacts on epithelial-mesenchymal transition and tumor vasculature.
  • Favorable safety profile observed in studies.

Conclusions:

  • Eribulin possesses unique properties for metastatic breast cancer treatment.
  • Its nonmitotic actions on vascular remodeling and tumor microenvironment suggest potential for immunological applications.
Keywords:
chemotherapyeribulinmechanism of actionmetastatic breast cancernew treatment

More Related Videos

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

842
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K